What do you get when you undertake a cost-benefit analysis of new therapies when prices have yet to be established… Read more »
By extending the peanut biologic oral immunotherapy known as AR101 by 28 weeks, a new study finds that a majority… Read more »
A Q&A with FARE about the consensus the non-profit hopes to achieve at a fall summit on OIT.
A systematic review of peanut oral immunotherapy that compared 12 controlled studies has brought a longstanding “pro or con” debate… Read more »
Using boiled peanut protein in oral immunotherapy treatment (OIT) is safe and effective, with fewer gastrointestinal symptoms compared to using… Read more »
In a long-term follow-up with 55 peanut-allergic children who had undergone oral or sublingual immunotherapy, 89 percent of patients followed… Read more »
The positive results of a pivotal Phase 3 study of a peanut biologic oral immunotherapy known as AR101 were published… Read more »
The FDA has given its “breakthrough therapy designation” to omalizumab, known by the brand Xolair, to be developed as a… Read more »
Hundreds of allergists turned out to see Dr. Stacie Jones present highly anticipated study results at the AAAAI/WAO joint congress… Read more »
Three experts dispute the claims that a new probiotic therapy is a breakthrough for peanut allergy.